Respiratory Institute Outcomes

Therapies for severe asthma have significantly advanced in recent years. The Asthma Center uses a personalized approach based on the type of asthma, often referred to as asthma phenotype or endotype, to determine the most appropriate treatment plan, including the use of biologic therapy for each patient. Biologics, or monoclonal antibodies, have become increasingly common in the treatment of moderate to severe asthma as they target different pathways of inflammation.¹ We had 248 new biologic prescriptions in 2022 from 12 Asthma Center providers in both Pulmonary and Allergy. New prescriptions for biologics increased in 2023 to 433, reflecting the higher volume of patients served in our clinics.